Disease: Conn Syndrome ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1384514
Disease: Conn Syndrome
Conn Syndrome 		0.100 Biomarker disease BEFREE The aim of this study was to review the clinical outcomes after mineralocorticoid receptor (MR) antagonist treatment versus adrenalectomy treatment in patients with PA. 30948836 2019
CUI: C1384514
Disease: Conn Syndrome
Conn Syndrome 		0.100 GeneticVariation disease BEFREE We included newly diagnosed patients with PA (n=26), and patients with PA after adrenalectomy (n=25) or treated with mineralocorticoid receptor antagonists (n=25). 30865926 2019
CUI: C1384514
Disease: Conn Syndrome
Conn Syndrome 		0.100 Biomarker disease BEFREE We measured active GLP-1 concentration in primary aldosteronism (PA) patients before and after the administration of MR antagonist eplerenone. 31091693 2019
CUI: C1384514
Disease: Conn Syndrome
Conn Syndrome 		0.100 Biomarker disease BEFREE Mineralocorticoid Receptor-Dependent Impairment of Baroreflex Contributes to Hypertension in a Mouse Model of Primary Aldosteronism. 31824340 2019
CUI: C1384514
Disease: Conn Syndrome
Conn Syndrome 		0.100 Biomarker disease BEFREE Primary aldosteronism (PA) is mainly treated by mineralocorticoid receptor antagonists or laparoscopic adrenalectomy (LA), but the effectiveness of surgical versus medical treatment in patients with adrenal venous sampling (AVS)-proven unilateral PA is unclear. 31488861 2019
CUI: C1384514
Disease: Conn Syndrome
Conn Syndrome 		0.100 Biomarker disease BEFREE Adrenal Vein Sampling Lateralization Despite Mineralocorticoid Receptor Antagonists Exposure in Primary Aldosteronism. 30239792 2019
CUI: C1384514
Disease: Conn Syndrome
Conn Syndrome 		0.100 Biomarker disease BEFREE Despite these imperatives, screening rates for PA are low, and mineralocorticoid-receptor antagonists are underused for hypertension treatment. 30359120 2018
CUI: C1384514
Disease: Conn Syndrome
Conn Syndrome 		0.100 Biomarker disease BEFREE Mineralocorticoid receptor antagonists result in significant improvement in blood pressure and serum potassium level among patients with primary aldosteronism. 30854950 2018
CUI: C1384514
Disease: Conn Syndrome
Conn Syndrome 		0.100 GeneticVariation disease BEFREE In 17 PA patients (6 APA and 11 IHA) the titer was evaluated under mineralocorticoid receptor (MR) antagonist treatment. 30058103 2018
CUI: C1384514
Disease: Conn Syndrome
Conn Syndrome 		0.100 Biomarker disease BEFREE Diagnostic utility of ARR and its components for PA diagnostics under MR blocker treatment warrants further study. 29723896 2018
CUI: C1384514
Disease: Conn Syndrome
Conn Syndrome 		0.100 GeneticVariation disease BEFREE Patients with PA who were treated with MR antagonists were categorized by whether their plasma renin activity remained suppressed (< 1 ng/mL/h) or substantially increased (≥ 1 ng/mL/h), as proxies for insufficient or sufficient MR blockade. 30027227 2018
CUI: C1384514
Disease: Conn Syndrome
Conn Syndrome 		0.100 Biomarker disease BEFREE Lifelong therapy with mineralocorticoid receptor antagonists (MRAs) or surgical adrenalectomy are the recommended treatments for primary aldosteronism (PA). 29987110 2018
CUI: C1384514
Disease: Conn Syndrome
Conn Syndrome 		0.100 GeneticVariation disease BEFREE The latter step is necessary to determine the optimal treatment approach of unilateral laparoscopic adrenalectomy (for patients with unilateral PA) or medical treatment with a mineralocorticoid receptor antagonist (for patients with bilateral PA). 29674485 2018
CUI: C1384514
Disease: Conn Syndrome
Conn Syndrome 		0.100 Biomarker disease BEFREE The current practice of MR antagonist therapy in primary aldosteronism is associated with significantly higher risk for incident cardiometabolic events and death, independent of blood pressure control, than for patients with essential hypertension. 29129576 2018
CUI: C1384514
Disease: Conn Syndrome
Conn Syndrome 		0.100 Biomarker disease BEFREE Primary aldosteronism is recognized as a severe form of renin-independent aldosteronism that results in excessive mineralocorticoid receptor (MR) activation. 29052707 2017
CUI: C1384514
Disease: Conn Syndrome
Conn Syndrome 		0.100 Biomarker disease BEFREE The frequency of hyperkalemia after medication using mineralocorticoid receptor antagonists (MRAs) for PA is unclear. 28540931 2017
CUI: C1384514
Disease: Conn Syndrome
Conn Syndrome 		0.100 Biomarker disease BEFREE Mineralocorticoid receptor antagonist therapy alone may not be sufficient to counteract adverse metabolic risk in medically treated patients with primary aldosteronism. 28422753 2017
CUI: C1384514
Disease: Conn Syndrome
Conn Syndrome 		0.100 Biomarker disease BEFREE A/C = cortisol-corrected aldosterone concentration; ACE = angiotensin-converting enzyme; APA = aldosterone-producing adenoma; APCC = aldosterone-producing cell cluster; ARB = angiotensin receptor blocker; ARR = aldosterone-to-renin ratio; AVS = adrenal venous sampling; CT = computed tomography; ENaC = epithelial sodium channel; GRA = glucocorticoid remediable aldosteronism; IHA = idiopathic hyperaldosteronism; LI = lateralization ratio; MR = mineralocorticoid receptor; MRI = magnetic resonance imaging; PA = primary aldosteronism; PRA = plasma renin activity; SRA = surgical remediable aldosteronism. 28332881 2017
CUI: C1384514
Disease: Conn Syndrome
Conn Syndrome 		0.100 Biomarker disease BEFREE GCs play key roles in skin pathophysiology acting through both GR and MR; however, the effects of aldosterone and the potential association of PA and skin disease were not previously addressed. 29150654 2017
CUI: C1384514
Disease: Conn Syndrome
Conn Syndrome 		0.100 Biomarker disease BEFREE Aldosterone producing adenoma and bilateral adrenal hyperplasia are the two most common subtypes of primary aldosteronism (PA) that require targeted and distinct therapeutic approaches: unilateral adrenalectomy or lifelong medical therapy with mineralocorticoid receptor antagonists. 28420172 2017
CUI: C1384514
Disease: Conn Syndrome
Conn Syndrome 		0.100 Biomarker disease BEFREE Twenty patients had repeat PSG performed after treatment for PA (mineralocorticoid receptor antagonists in 13 with bilateral PA and adrenalectomy in 7 with unilateral PA).In this group the median (s.d.) 28382959 2017
CUI: C1384514
Disease: Conn Syndrome
Conn Syndrome 		0.100 GeneticVariation disease BEFREE Mineralocorticoid receptor antagonist (MRA) treatment might be associated with higher risk of osteoporotic fracture in the whole female PA cohort (subdistribution hazard ratio [SHR] = 2.12, p = 0.008) as well as female APA patients (SHR = 1.15, p = 0.049). 27862274 2017
CUI: C1384514
Disease: Conn Syndrome
Conn Syndrome 		0.100 Biomarker disease BEFREE New questions for the next 5 years include a single accepted confirmatory/exclusion test; standardisation of assays and cut-offs; alternatives to universal adrenal venous sampling; reclassification of 'low renin hypertension'; recognition of the extent of 'occult' PA; inclusion of low-dose mineralocorticoid receptor antagonist in first-line therapy for hypertension; and finally, possible resolution of the aldosterone/inappropriate sodium status enigma at the heart of the cardiovascular damage in PA. 26588848 2015
CUI: C1384514
Disease: Conn Syndrome
Conn Syndrome 		0.100 Biomarker disease BEFREE Mineralocorticoid receptor antagonists (MRAs) have effectively been used for the treatment of patients with hypertension who do not have primary aldosteronism (PA). 25974737 2015
CUI: C1384514
Disease: Conn Syndrome
Conn Syndrome 		0.100 Biomarker disease BEFREE The antihypertensive efficacy of mineralocorticoid-receptor blockers, even in patients with aldosterone values in the normal range, supports the evidence that aldosterone plays a part in blood pressure elevation in the absence of primary aldosteronism. 20027193 2010